Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00279734 | Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers | PHASE1 | COMPLETED | 80 | — | — | Aug 1, 2004 | Jan 1, 2005 | Apr 13, 2011 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Group 3 | ACTIVE_COMPARATOR | - |
| Group 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Tetanus + pnemococcal vaccines alone | DRUG | 0 mg + vaccines, Single dose, 28 days. |
| Abatacept + vaccines | DRUG | Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days. |
Inclusion Criteria: * Healthy Subjects * Body Weight between 60 and 100 kg. * Males and Females must be using adequate contraceptive methods during study and for 10 weeks after dose of study mediciation. Exclusion Criteria: * Females who are prgnant or breastfeeding * History of autoimmune disord...